132 related articles for article (PubMed ID: 9031617)
1. APC resistance as an additional thrombotic risk factor in a patient suffering from polycythemia vera and recurrent thrombosis.
Lamparter S; Schuermann M; Heidtmann HH
Ann Hematol; 1997 Jan; 74(1):49-50. PubMed ID: 9031617
[TBL] [Abstract][Full Text] [Related]
2. Thrombotic complications of polycythemia vera.
Varma S; Sharma A; Malhotra P; Kumari S; Jain S; Varma N
Hematology; 2008 Dec; 13(6):319-23. PubMed ID: 19055858
[TBL] [Abstract][Full Text] [Related]
3. Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea.
Alvarez-Larrán A; Pérez-Encinas M; Ferrer-Marín F; Hernández-Boluda JC; Ramírez MJ; Martínez-López J; Magro E; Cruz Y; Mata MI; Aragües P; Fox ML; Cuevas B; Montesdeoca S; Hernández-Rivas JA; García-Gutiérrez V; Gómez-Casares MT; Steegmann JL; Durán MA; Gómez M; Kerguelen A; Bárez A; García MC; Boqué C; Raya JM; Martínez C; Albors M; García F; Burgaleta C; Besses C;
Haematologica; 2017 Jan; 102(1):103-109. PubMed ID: 27686377
[TBL] [Abstract][Full Text] [Related]
4. Acute coronary disease in essential thrombocythemia and polycythemia vera.
Rossi C; Randi ML; Zerbinati P; Rinaldi V; Girolami A
J Intern Med; 1998 Jul; 244(1):49-53. PubMed ID: 9698024
[TBL] [Abstract][Full Text] [Related]
5. Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden.
Lim Y; Lee JO; Kim SH; Kim JW; Kim YJ; Lee KW; Lee JS; Bang SM
Thromb Res; 2015 May; 135(5):846-51. PubMed ID: 25743883
[TBL] [Abstract][Full Text] [Related]
6. "Pseudo homozygous" activated protein C resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds.
Simioni P; Scudeller A; Radossi P; Gavasso S; Girolami B; Tormene D; Girolami A
Thromb Haemost; 1996 Mar; 75(3):422-6. PubMed ID: 8701401
[TBL] [Abstract][Full Text] [Related]
7. Anticoagulant-resistant thrombophilia in a patient with polycythemia vera: a case report.
Das S; Karachiwala H; Cherian SV; Garcha AS; Jasti S; Gajra A
Blood Coagul Fibrinolysis; 2011 Dec; 22(8):746-8. PubMed ID: 21885951
[TBL] [Abstract][Full Text] [Related]
8. Thrombotic risk factors and oral contraception.
Bokarewa MI; Falk G; Sten-Linder M; Egberg N; Blombäck M; Bremme K
J Lab Clin Med; 1995 Sep; 126(3):294-8. PubMed ID: 7665978
[TBL] [Abstract][Full Text] [Related]
9. Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia.
Ruggeri M; Gisslinger H; Tosetto A; Rintelen C; Mannhalter C; Pabinger I; Heis N; Castaman G; Missiaglia E; Lechner K; Rodeghiero F
Am J Hematol; 2002 Sep; 71(1):1-6. PubMed ID: 12221665
[TBL] [Abstract][Full Text] [Related]
10. Polycythemia vera and hydroxyurea resistance/intolerance: a monocentric retrospective analysis.
Demuynck T; Verhoef G; Delforge M; Vandenberghe P; Devos T
Ann Hematol; 2019 Jun; 98(6):1421-1426. PubMed ID: 30919072
[TBL] [Abstract][Full Text] [Related]
11. The relationship between factor V Leiden, prothrombin G20210A, and MTHFR mutations and the first major thrombotic episode in polycythemia vera and essential thrombocythemia.
Trifa AP; Cucuianu A; Popp RA; Coadă CA; Costache RM; Militaru MS; Vesa ŞC; Pop IV
Ann Hematol; 2014 Feb; 93(2):203-9. PubMed ID: 23828072
[TBL] [Abstract][Full Text] [Related]
12. Hemostatic gene polymorphisms and the prevalence of thrombotic complications in polycythemia vera and essential thrombocythemia.
Afshar-Kharghan V; López JA; Gray LA; Padilla A; Borthakur G; Roberts SC; Pruthi RK; Tefferi A
Blood Coagul Fibrinolysis; 2004 Jan; 15(1):21-4. PubMed ID: 15166939
[TBL] [Abstract][Full Text] [Related]
13. Laboratory investigations and prediction of thrombotic risk in polycythemia vera.
Boneu B
Nouv Rev Fr Hematol (1978); 1994 Apr; 36(2):183-5. PubMed ID: 8036139
[TBL] [Abstract][Full Text] [Related]
14. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia.
Michiels JJ; Berneman Z; Schroyens W; Koudstaal PJ; Lindemans J; Neumann HA; van Vliet HH
Platelets; 2006 Dec; 17(8):528-44. PubMed ID: 17127481
[TBL] [Abstract][Full Text] [Related]
15. Polycythemia vera and mesenteric arterial thrombosis. A disease association resulting from decreased platelet sensitivity to aspirin.
Myers TJ; Steinberg WM; Rickles FR
Arch Intern Med; 1979 Jun; 139(6):695-8. PubMed ID: 443976
[TBL] [Abstract][Full Text] [Related]
16. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
Tefferi A
Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582
[TBL] [Abstract][Full Text] [Related]
17. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.
De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Marchioli R; Leone G; Barbui T;
Haematologica; 2008 Mar; 93(3):372-80. PubMed ID: 18268279
[TBL] [Abstract][Full Text] [Related]
18. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C.
Zöller B; Svensson PJ; He X; Dahlbäck B
J Clin Invest; 1994 Dec; 94(6):2521-4. PubMed ID: 7989612
[TBL] [Abstract][Full Text] [Related]
19. Resistance to activated protein C (APC): mutation at Arg506 of coagulation factor V and vascular access thrombosis in haemodialysis patients.
Födinger M; Mannhalter C; Pabinger I; Koizar D; Rintelen C; Hörl WH; Sunder-Plassmann G
Nephrol Dial Transplant; 1996 Apr; 11(4):668-72. PubMed ID: 8671856
[TBL] [Abstract][Full Text] [Related]
20. Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera.
Alvarez-Larrán A; Pereira A; Cervantes F; Arellano-Rodrigo E; Hernández-Boluda JC; Ferrer-Marín F; Angona A; Gómez M; Muiña B; Guillén H; Teruel A; Bellosillo B; Burgaleta C; Vicente V; Besses C
Blood; 2012 Feb; 119(6):1363-9. PubMed ID: 22160617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
